Hermetica Superfood Encyclopedia
The Short Answer
Prunus africana bark delivers pentacyclic triterpenoids—ursolic acid (743 mg/kg), β-sitosterol (490 mg/kg), and β-sitostenone (198 mg/kg)—that collectively inhibit 5α-reductase enzyme activity, suppress prostatic inflammation, and modulate androgenic signaling to address benign prostatic hyperplasia. Preclinical evidence from 20 African populations demonstrates that these phytosterols and triterpenoids synergistically reduce dihydrotestosterone-mediated prostate cell proliferation, though large-scale human clinical trials with published effect sizes remain limited.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordPrunus africana bark benefits
African Cherry Orange — botanical close-up
Health Benefits
**Benign Prostatic Hyperplasia (BPH) Relief**
β-Sitosterol (490 mg/kg bark) and β-sitostenone competitively inhibit 5α-reductase, reducing conversion of testosterone to dihydrotestosterone and thereby decreasing prostatic cell hyperplasia and urinary obstruction symptoms.
**Anti-Inflammatory Activity**
Oleanolic acid and ursolic acid suppress cyclooxygenase-2 (COX-2), nitric oxide synthase, and IFN-γ in macrophages, attenuating the chronic inflammatory signaling that promotes prostatic enlargement and tissue damage.
**Antioxidant Protection**
Ferulic acid (49 mg/kg) and flavonoids drive DPPH radical scavenging activity that correlates positively with total phenolic content (0.26 mg/g in methanolic extract), protecting prostatic tissue from oxidative stress-induced damage.
**Antiandrogenic Modulation**
β-Sitostenone and ferulic acid exhibit antiandrogenic properties by impeding testosterone and dihydrotestosterone receptor interactions, which may restore hormonal balance in BPH without ablating testosterone production entirely.
**Apoptosis Induction in Prostate Cells**
Oleanolic acid activates AMPK signaling in PC-3 prostate cancer cells to promote apoptosis, while ursolic acid and β-amyrins further inhibit tumor cell proliferation by disrupting cell cycle progression.
**Lipid Peroxidation Prevention**
Myristic acid (22 mg/kg) provides membrane-stabilizing antioxidant effects that prevent lipid peroxidation in prostatic tissue, reducing oxidative damage associated with chronic BPH progression.
**Phase-2 Enzyme Induction**
Oleanolic acid upregulates heme oxygenase-1 and NADH-quinone oxidoreductase, cytoprotective phase-2 detoxification enzymes that neutralize reactive oxygen species and electrophilic toxins in prostate and systemic tissues.
Origin & History
Natural habitat
Prunus africana is a large Afromontane tree native to sub-Saharan Africa, growing at elevations of 1,000–3,000 meters across East and West African highland forests in countries including Cameroon, Kenya, Uganda, Ethiopia, and Madagascar. The tree thrives in moist, montane forest ecosystems and is harvested primarily for its bark, which is stripped from wild populations rather than cultivated plantations, making sustainable sourcing a persistent conservation challenge. Overharvesting driven by global demand for bark extracts has led to the species being listed on CITES Appendix II, restricting international trade without regulated permits.
“Prunus africana bark has been employed for centuries in the traditional medicine systems of East and Central African communities—including healers in Cameroon, Kenya, Uganda, and Madagascar—primarily for the treatment of urinary difficulties, benign prostatic hypertrophy, chest pain, fever, and kidney disease, positioning it as one of the most economically significant medicinal trees in Afromontane ecosystems. In Cameroonian ethnobotany, the tree is known as 'Pygeum' by traders and 'bitter almond' in regional contexts, and bark preparations were traditionally administered as decoctions brewed by community healers and prescribed for male reproductive health complaints that align precisely with contemporary BPH symptomatology. The species gained international commercial prominence in the 1960s when French pharmaceutical researchers extracted and standardized its lipophilic bark constituents for the European market, creating a proprietary extract sold under the brand name Tadenan and generating export demand that ultimately drove unsustainable harvesting pressures across its native range. By the 1990s, the scale of wild bark harvesting—estimated at 3,000–4,500 metric tons of dried bark annually at peak demand—prompted CITES listing and international conservation interventions that continue to shape both local livelihoods and the global supply chain for this ingredient.”Traditional Medicine
Scientific Research
The evidence base for Prunus africana is predominantly preclinical, derived from in vitro biochemical assays, GC-MSD phytochemical analyses across 20 geographically distinct African populations, and animal model studies, with no published large-scale randomized controlled trials providing sample sizes, p-values, or validated effect sizes in the peer-reviewed literature currently indexed. Phytochemical characterization studies have rigorously quantified bioactive compounds—ursolic acid at 743 mg/kg with 66% population variance, β-sitosterol at 490 mg/kg with only 20% variance—and have demonstrated that ferulic acid concentrations correlate significantly with annual precipitation at source locations, indicating environmentally driven chemotypic variability that complicates standardization. In vitro studies have confirmed 5α-reductase inhibitory activity of bark fractions and AMPK-mediated apoptosis in PC-3 prostate cancer cell lines by oleanolic acid, and DPPH radical scavenging activity has been positively correlated with total phenolic content (0.26 mg/g) and flavonoid levels in methanolic extracts. While the proprietary European standardized lipophilic bark extract (marketed as Pygeum africanum extract in older literature) has been evaluated in European clinical trials primarily conducted in the 1980s–1990s showing modest improvement in urinary flow metrics, the methodological quality of those trials was limited by small sample sizes and short follow-up periods, and they do not fully represent the raw botanical evidence profile described here.
Preparation & Dosage
Traditional preparation
**Traditional Bark Decoction**
Bark strips are simmered in water for 20–40 minutes to prepare a decoction consumed orally 1–2 times daily; no standardized volume has been validated in clinical trials.
**Standardized Lipophilic Bark Extract (Historical European Preparations)**
100–200 mg daily of lipophilic extract (standardized to phytosterol content) were used in older BPH clinical trials, typically taken in divided doses with meals
Doses of .
**Methanolic/Ethyl Acetate Extract (Research Grade)**
Sequentially extracted laboratory preparations yield approximately 11.9% extract from dry bark weight and are used in preclinical in vitro studies; no human dose established from this form.
**Bark Powder (Traditional)**
1–3 g daily in traditional African medicine contexts, typically mixed with water or porridge, though dose standardization is absent
Ground bark powder administered as .
**Bioavailability Note**
No formal pharmacokinetic data exist for ursolic acid, β-sitosterol, or oleanolic acid from Prunus africana specifically; general phytosterol bioavailability is low (~1–5%) without lipid-based delivery, suggesting fat co-administration or lipophilic extraction may optimize absorption.
**Standardization Consideration**
Significant population variance in ursolic acid content (66% coefficient of variation) necessitates third-party verification of batch phytochemical concentrations before therapeutic use.
Nutritional Profile
Prunus africana bark is not a macronutrient-dense food source but is rich in pharmacologically active secondary metabolites: pentacyclic triterpenoids including ursolic acid (743 mg/kg bark), oleanolic acid, and β-amyrins constitute the dominant bioactive fraction. Phytosterols—particularly β-sitosterol (490 mg/kg) and β-sitostenone (198 mg/kg)—represent a second major class, with low inherent bioavailability (~1–5%) requiring lipophilic extraction or fat co-ingestion to enhance absorption. Phenolic acids include ferulic acid (49 mg/kg, precipitation-correlated) contributing to a total phenolic content of approximately 0.26 mg/g in methanolic extract, alongside qualitatively identified flavonoids, tannins, saponins, and alkaloids. Fatty acid constituents include myristic acid (22 mg/kg), lauric acid (18 mg/kg), and n-docosanol (25 mg/kg), with high myristic acid concentrations specifically noted in stem bark fractions; these fatty acids contribute membrane-stabilizing and antioxidant properties rather than caloric nutritional value.
How It Works
Mechanism of Action
Prunus africana bark extracts exert their primary anti-BPH mechanism through competitive inhibition of 5α-reductase by ferulic acid, ursolic acid, and phytosterols—particularly β-sitosterol and β-sitostenone—which reduce the enzymatic conversion of testosterone to the more potent androgen dihydrotestosterone (DHT) in prostatic stromal and epithelial cells. Oleanolic acid independently targets AMP-activated protein kinase (AMPK) in prostate cells to trigger intrinsic apoptotic cascades, while simultaneously inhibiting COX-2 and inducible nitric oxide synthase (iNOS) in macrophages to resolve chronic prostatic inflammation. Ferulic acid and flavonoid constituents contribute antioxidant activity through direct DPPH radical scavenging correlated with phenolic content, protecting cellular membranes from lipid peroxidation, and oleanolic acid induces cytoprotective phase-2 enzymes including heme oxygenase-1 and NADH-quinone oxidoreductase to amplify endogenous antioxidant defenses. The synergy of triterpenoids, phytosterols, and phenolic acids across these parallel pathways—5α-reductase inhibition, AMPK activation, COX-2 suppression, and free radical quenching—is considered responsible for the clinical utility of bark extracts in managing BPH.
Clinical Evidence
Formal human clinical trials using raw Prunus africana bark extracts with published statistical outcomes are absent from the contemporary peer-reviewed database, representing a significant gap between traditional use prevalence and evidence-based substantiation. The most cited human evidence derives from older European trials of a standardized lipophilic bark extract evaluated for BPH, which demonstrated improvements in International Prostate Symptom Scores and peak urinary flow rates, but these trials enrolled fewer than 200 patients cumulatively, lacked placebo arms in several cases, and used proprietary extraction protocols not fully comparable to traditional preparations. Preclinical evidence robustly supports the mechanistic plausibility of BPH efficacy through phytosterol-mediated 5α-reductase inhibition and oleanolic acid-driven apoptosis, but translational gap analysis indicates that dose-response relationships, bioavailability in humans, and long-term safety have not been adequately characterized in controlled studies. Confidence in clinical benefit is moderate for symptomatic BPH relief based on mechanistic and historical data, but remains preliminary by contemporary evidence standards due to the absence of recent, adequately powered randomized controlled trials.
Safety & Interactions
Prunus africana bark extracts have not been associated with serious adverse events in traditional use contexts, and no formal toxicological studies establishing LD50 values or maximum tolerated doses in humans have been published for the raw botanical; older European clinical trials of proprietary lipophilic extracts reported minimal gastrointestinal side effects at 100–200 mg daily doses. The antiandrogenic activity of β-sitostenone and ferulic acid—inhibiting testosterone and dihydrotestosterone receptor interactions—warrants caution in individuals with hormone-sensitive conditions, including hormone-receptor-positive cancers, and the extract should theoretically be used with caution alongside pharmaceutical 5α-reductase inhibitors such as finasteride or dutasteride due to potential pharmacodynamic additive effects on DHT suppression. No formal drug interaction data are published for Prunus africana bark with anticoagulants, antiplatelet agents, or cytochrome P450 substrates, representing a critical safety evidence gap. Pregnancy and lactation safety data are entirely absent, and given the antiandrogenic and hormonal modulatory activity, use during pregnancy or in pediatric populations should be avoided until safety data are established.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Pygeum africanumRed stinkwoodAfrican cherryPrunus africanaTadenan extractAfrican Cherry Orange (Citropsis articulata)Bitter almond (Cameroon)
Frequently Asked Questions
What does Prunus africana bark do for the prostate?
Prunus africana bark contains β-sitosterol (490 mg/kg) and β-sitostenone that inhibit 5α-reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT), reducing DHT-driven prostate cell proliferation characteristic of benign prostatic hyperplasia (BPH). Oleanolic acid further induces apoptosis in prostate cells via AMPK activation and suppresses prostatic inflammation through COX-2 and nitric oxide synthase inhibition. Collectively, these compounds address both the hormonal and inflammatory mechanisms underlying BPH symptomatology.
What are the main bioactive compounds in African cherry orange bark?
The primary bioactive compounds in Prunus africana bark are pentacyclic triterpenoids—ursolic acid at approximately 743 mg/kg, oleanolic acid, and β-amyrins—alongside phytosterols including β-sitosterol (490 mg/kg) and β-sitostenone (198 mg/kg). Phenolic acids such as ferulic acid (49 mg/kg) and fatty acids including myristic acid (22 mg/kg) and lauric acid (18 mg/kg) contribute antioxidant and anti-inflammatory properties. Concentrations vary significantly across geographic populations, with ursolic acid showing a 66% coefficient of variation across 20 African sourcing populations.
Is there clinical trial evidence for Prunus africana treating BPH?
Formal large-scale randomized controlled trials for raw Prunus africana bark extracts with published effect sizes and p-values are currently lacking in the peer-reviewed literature. Older European clinical trials of a proprietary standardized lipophilic bark extract (marketed as Tadenan) showed modest improvements in International Prostate Symptom Scores and peak urinary flow, but these enrolled fewer than 200 patients cumulatively and had methodological limitations. The current evidence base is therefore classified as preliminary to moderate, with mechanistic preclinical data being more robust than human clinical trial data.
What is the recommended dosage of African cherry orange (Pygeum) extract?
No universally validated dosage for raw Prunus africana bark extracts has been established through modern clinical trials. Older European research on standardized lipophilic bark extract used doses of 100–200 mg daily, typically divided into two doses taken with meals to enhance absorption of fat-soluble phytosterols and triterpenoids. Traditional African preparations use bark decoctions or 1–3 g of bark powder daily, though these lack pharmacokinetic standardization; significant batch-to-batch variability in bioactive content (particularly ursolic acid) necessitates third-party certificate of analysis verification for any supplement.
Are there any side effects or drug interactions with Prunus africana bark?
Prunus africana bark extracts are generally considered well-tolerated based on historical traditional use, with older clinical trials reporting only mild gastrointestinal effects at 100–200 mg daily of standardized extract. However, the antiandrogenic activity of its phytosterols may interact pharmacodynamically with pharmaceutical 5α-reductase inhibitors (finasteride, dutasteride) causing additive DHT suppression, and use alongside hormone therapies for hormone-sensitive cancers warrants medical supervision. Pregnancy and lactation safety data are entirely absent, and women who are pregnant or breastfeeding should avoid use; individuals on hormonal medications or antiandrogen therapies should consult a healthcare provider before supplementing.
Is African cherry orange (Prunus africana) safe for women to take?
Prunus africana bark is traditionally and clinically studied primarily in men with benign prostatic hyperplasia, and safety data in women is limited. While the herb is generally well-tolerated with few reported adverse effects in studied populations, women should consult a healthcare provider before use, particularly those who are pregnant or breastfeeding, as reproductive hormone effects have not been thoroughly evaluated in female populations.
How does African cherry orange compare to saw palmetto for prostate health?
Both Prunus africana and saw palmetto (Serenoa repens) are used for BPH symptom relief, but they work through different mechanisms—Prunus africana primarily inhibits 5α-reductase via β-sitosterol, while saw palmetto acts through multiple pathways including 5α-reductase inhibition and anti-inflammatory effects. Clinical evidence supports both for mild to moderate BPH symptoms, though direct comparative trials are limited, and individual response varies based on the specific extract composition and bioactive concentration.
What is the most bioavailable form of Prunus africana extract?
Standardized lipophilic extracts of Prunus africana bark (such as Pygeum africanum extracts standardized to 14% β-sitosterol and other lipophilic compounds) demonstrate superior bioavailability compared to crude bark powder due to enhanced absorption of fat-soluble bioactive compounds. The extraction method, solvent used, and standardization of β-sitosterol content significantly influence both the concentration of active constituents and their intestinal absorption rates.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w african-cherry-orange-prunus-africana curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
